Wedbush Upgrades Black Diamond Therapeutic to Outperform, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has upgraded Black Diamond Therapeutic (NASDAQ:BDTX) from Neutral to Outperform and raised the price target from $3 to $10.
June 27, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutic has been upgraded to Outperform by Wedbush, with a price target increase from $3 to $10.
The upgrade from Neutral to Outperform by a Wedbush analyst and the significant increase in price target from $3 to $10 indicates a positive outlook for Black Diamond Therapeutic. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100